Wellington Management Group LLP Sells 790,748 Shares of Progyny, Inc. $PGNY

Wellington Management Group LLP lessened its position in shares of Progyny, Inc. (NASDAQ:PGNY) by 34.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,496,633 shares of the company’s stock after selling 790,748 shares during the quarter. Wellington Management Group LLP owned approximately 1.95% of Progyny worth $43,148,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Caitong International Asset Management Co. Ltd bought a new position in Progyny in the fourth quarter worth $25,000. Public Employees Retirement System of Ohio acquired a new stake in Progyny during the second quarter worth $29,000. Hantz Financial Services Inc. increased its holdings in Progyny by 79.4% in the 4th quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock valued at $43,000 after buying an additional 742 shares during the period. Quarry LP increased its holdings in Progyny by 2,004.1% in the 3rd quarter. Quarry LP now owns 3,598 shares of the company’s stock valued at $77,000 after buying an additional 3,427 shares during the period. Finally, Canada Pension Plan Investment Board acquired a new position in shares of Progyny in the 2nd quarter valued at $77,000. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Progyny Stock Performance

Shares of NASDAQ:PGNY opened at $26.61 on Friday. Progyny, Inc. has a 52 week low of $16.10 and a 52 week high of $33.06. The company’s fifty day moving average is $29.02 and its 200-day moving average is $23.78. The company has a market capitalization of $2.04 billion, a PE ratio of 28.92, a P/E/G ratio of 1.81 and a beta of 0.99.

Progyny (NASDAQ:PGNY) last posted its earnings results on Thursday, August 6th. The company reported $0.55 earnings per share for the quarter, topping the consensus estimate of $0.33 by $0.22. The business had revenue of $350.51 million for the quarter, compared to analyst estimates of $349.05 million. Progyny had a net margin of 6.00% and a return on equity of 15.98%. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.19 EPS. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. On average, analysts forecast that Progyny, Inc. will post 1.25 EPS for the current year.

Progyny announced that its board has authorized a stock buyback program on Tuesday, May 26th that permits the company to buyback $200.00 million in shares. This buyback authorization permits the company to reacquire up to 10.3% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s management believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Wall Street Zen downgraded shares of Progyny from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 25th. BTIG Research increased their price target on shares of Progyny from $30.00 to $40.00 and gave the stock a “buy” rating in a research report on Friday, July 24th. Zacks Research upgraded shares of Progyny from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, July 8th. Bank of America lifted their price objective on Progyny from $29.00 to $31.00 and gave the company a “buy” rating in a report on Tuesday, June 2nd. Finally, Canaccord Genuity Group set a $35.00 price objective on Progyny in a research note on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $33.91.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.